medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2018, Number 1

<< Back Next >>

Rev Invest Clin 2018; 70 (1)

A prognostic score for survival in patients older than 65 years with Diffuse Large B-Cell Lymphoma

Candelaria M, Reynoso-Noverón N, Ponce M, Castillo-Llanos R, Nolasco-Medina D, Cantú-de-Leon D

Language: English
References: 26
Page: 46-52
PDF size: 142.77 Kb.


ABSTRACT

Background: Available prognosis scores for patients with diffuse large B-cell lymphoma (DLBCL) included a limited number of patients ≥ 65 years of age, and most of them did not include comorbidities. Here, we propose a prognostic score for overall survival (OS) for this group of patients. Materials and Methods: Patients ≥ 65 years with DLBCL treated at a single national reference center were included. Clinical features including comorbidities and biochemical parameters were analyzed. Results: We included 141 patients. Response rate in the whole group was 77%. Based on multivariate analysis, the presence of the European Cooperative Oncology Group (ECOG) › 2, elevated levels of beta-2 microglobulin, bulky disease, and anemia (hemoglobin ‹ 10 g/dL) had a significant effect on OS. These parameters were considered when computing the prognostic score, which identified three groups with differential survival: Low, intermediate, and high risk of death, with a probability of survival at 60 months of 80.05%, 55.5%, and 29.84%, respectively. Discussion: This score may select patients to optimize treatment. The presence of high levels of beta-2 microglobulin, bulky disease, and hemoglobin ‹ 10 g/dL, and ECOG › 2 was associated with poor OS in elderly patients with DLBCL.


REFERENCES

  1. Available from: http://www.apps.who.int/gho/data/view.main. SDG2016LEXREGv?lang=en. [Last accessed on 2016 Nov 23].

  2. Conde-Sala JL, Portellano-Ortiz C, Calvó-Perxas L, Garre-Olmo J. Quality of life in people aged 65+ in Europe: Associated factors and models of social welfare-analysis of data from the SHARE project (Wave 5). Qual Life Res. 2017;26:1059-70.

  3. Ferlay J, Soerjomataram I, Ervik M. GLOBOCAN 2015 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No 11. Lyon, France: International Agency for Research on Cancer. Available from: http://www.globocan.iarc.fr. [Last addressed on 2017 Sep 10].

  4. Candelaria M. Advances in diagnosis and control of lymphomas. Salud Publica Mex. 2016;58:296-301.

  5. Nabhan C, Smith SM, Helenowski I, et al. Analysis of very elderly (≥80 years) non-hodgkin lymphoma: Impact of functional status and comorbidities on outcome. Br J Haematol. 2012;156: 196-204.

  6. Varga C, Holcroft C, Kezouh A, et al. Comparison of outcomes among patients aged 80 and over and younger patients with diffuse large B-cell lymphoma: A population based study. Leuk Lymphoma. 2014;55:533-7.

  7. Xue QL. The frailty syndrome: Definition and natural history. Clin Geriatr Med. 2011;27:1-5.

  8. Hermans J, Krol AD, van Groningen K, et al. International prognostic index for aggressive non-hogkin’s lymphoma is valid for all malignancy grades. Blood. 1995;86:1460-63.

  9. Sehn LH, Berry B, Chhanabhai M, et al. The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857-61.

  10. Conill C, Verger E, Salamero M. Performance status assessment in cancer patients. Cancer. 1990;65:1864-6.

  11. Katoh D, Ochi Y, Yabushita T, et al. Peripheral blood lymphocyte- to-monocyte ratio at relapse predicts outcome for patients with relapsed or refractory diffuse large B-cell lymphoma in the rituximab era. Clin Lymphoma Myeloma Leuk. 2017;17:e91-7.

  12. Zelenetz AD, Gordon LI, Wierda WG, et al. Diffuse large B-cell lymphoma version 1.2016. J Natl Compr Canc Netw. 2016;14: 196-231.

  13. Meignan M, Gallamini A, Haioun C, et al. Report on the 5th international workshop on positron emission tomography in lymphoma held in Menton, France, 19-20 September 2014. Leuk Lymphoma. 2015;56:1229-32.

  14. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-86.

  15. Ochi Y, Kazuma Y, Hiramoto N, et al. Utility of a simple prognostic stratification based on platelet counts and serum albumin levels in elderly patients with diffuse large B cell lymphoma. Ann Hematol. 2017;96:1-8.

  16. Byun JM, Lee JO, Kang B, et al. Diffuse large B-cell lymphoma in the elderly: Real world outcomes of immunochemotherapy in Asian population. Clin Lymphoma Myeloma Leuk. 2016;16:503-10.

  17. Adams HJ, de Klerk JM, Fijnheer R, et al. Prognostic value of anemia and C-reactive protein levels in diffuse large B cell lymphoma. Clin Lymphoma Myeloma Leuk. 2015;15:671-9.

  18. Xin LJ, Yang B, Lu XC, Yin P, Tian Y, Zhu HL. Prognostic and therapeutic significance of molecular subtyping on aged patient with advanced diffuse large B-cl lymphoma. A case report. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016;24:457-62.

  19. Kong Y, Qu L, Li Y, et al. Predictive significance of a new prognostic score for patients with diffuse large B-cell lymphoma in the interim-positron emission tomography findings. Medicine (Baltimore). 2016;95:e2808.

  20. Melchardt T, Troppan K, Weiss L, et al. Independent prognostic value of serum markers in diffuse large B-cell lymphoma in the era of the NCCN-IPI. J Natl Compr Canc Netw. 2015;13:1501-8.

  21. Troppan KT, Melchardt T, Wenzl K, et al. The clinical significance of fibrinogen plasma levels in patients with diffuse large B cell lymphoma. J Clin Pathol. 2016;69:326-30.

  22. Maurer MJ, Jais JP, Ghesquières H, et al. Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. Am J Hematol. 2016;91:179-84.

  23. Hantaweepant C, Chinthammitr Y, Khuhapinant A, Sukpanichnant S. Clinical significance of bone marrow involvement as confirmed by bone marrow aspiration vs. Bone marrow biopsy in diffuse large B-cell lymphoma. J Med Assoc Thai. 2016;99:262-9.

  24. Jung YH, Woo IS, Han CW. Clinical characteristics and outcomes in diffuse large B cell lymphoma patients aged 70 years and older: A single-center experience with a literature review Korean J Intern Med. 2015;30:684-93.

  25. Chuang WY, Chang H, Shin L, et al. CD5 positivity is an independent adverse prognostic factor in elderly patients with diffuse large B-cell lymphoma. Virchows Arch 2015;467:571-82.

  26. Xu-Monette ZY, Dabaja BS, Wang X, et al. Clinical features, tumor biology, and prognosis associated with MYC rearrangement and myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol. 2015;28:1555-73.




2020     |     www.medigraphic.com